Prognosis and treatment of complications associated with COVID-19: a systematic review and meta-analysis

• Main Authors: Xudong Xie (Author), Liangcong Hu (Author), Hang Xue (Author), Yuan Xiong (Author), Adriana C. Panayi (Author), Ze Lin (Author), Lang Chen (Author), Chenchen Yan (Author), Wu Zhou (Author), Bobin Mi (Author), Guohui Liu (Author)
• Format: Book
• Published: Compuscript Ltd, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2737-7946; 10.15212/AMM-2022-0002
• Keywords: covid-19; sars-cov-2; complications; prognosis; treatment; Pharmacy and materia medica; RS1-441; Therapeutics. Pharmacology; RM1-950
• Source: Acta Materia Medica, Vol 1, Iss 1, Pp 124-137 (2022)

The Coronavirus Disease 2019 (COVID-19) pandemic has been estimated to have claimed more than 6 million lives, and most deaths have been attributed to complications non-specific to the virus. Therefore, understanding and treating these complications are imperative. In this meta-analysis, we reviewed 181 studies published in early stages of the COVID-19 pandemic. We presented that the complications with high incidence among all COVID-19 cases were acute respiratory distress syndrome (ARDS, 18.52%), respiratory failure (16.54%), liver injury (14.13%) and multiple-organ dysfunction syndrome (MODS, 13.62%). Among patients who died, the most common complications were ARDS (84.10%), respiratory failure (78.75%) and respiratory injury (75.72%). Subsequently, we analyzed the risk factors for complications, and reviewed the currently available therapies according to complications and prognosis. To decrease the prevalence of COVID-19 complications and mortality, healthcare workers and patients should pay greater attention to the complications identified herein, particularly those occurring preclinically.